Diabetes groups slams NICE draft "no" for Lucentis in DMO
Diabetes groups slams NICE draft "no" for Lucentis in DMO: "The National Institute for Health and Clinical Excellence (NICE)'s final draft guidance rejecting the use of Novartis' Lucentis (ranibizumab) for the treatment of diabetic macular oedema (DMO) has been condemned by the charity Diabetes UK. ...
